Fundraising Fox
/Companies
Sign in

Alphina Therapeutics

New Haven, US · Founded 2021 · Delaware corporation · 4 known investors

Find your way into Alphina Therapeutics

262 people in our graph share verified history with the Alphina Therapeutics team — schools, employers, funds. One of them is your warm intro.

Axel Bolteunlockedknows Stanley Choy · together at Kolltan Pharmaceuticals, Inc. (overlapped)
×11knows the team · via Shearman & Sterling LLP

Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.

Biotech

Founders & leadership

BFBarbara Fox
Barbara FoxExecutive
NJ
Nicholas J GalliExecutive
SCStanley Choy
Stanley ChoyChief Financial OfficerStanley Choy is an executive officer at Alphina Therapeutics with over 25 years of healthcare and biotechnology experience, including roles as Chief Financial Officer at Edwards, Angell, Palmer & Dodge LLP, Financial Controller at Sherman & Sterling LLP, and senior finance positions at Pfizer Inc.
RBRanjit Bindra
Ranjit BindraCo-FounderOperating Partner at HighCape Capital

Board

CCColleen Cuffaro
Colleen CuffaroBoard directorPartner at Canaan Partners
MCMatthew Cohen
Matthew CohenBoard directorManaging Partner at OUP (Osage University Partners)
AAAnurag Agarwal
Anurag AgarwalBoard directorPartner at OUP (Osage University Partners)
KRKevin Rakin
Kevin RakinBoard directorPartner at HighCape Capital

Investors · 4

Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M

How we know: Connecticut Innovations's portfolio page · Not right? Tell us

HighCape Capitallisted by HighCape CapitalWestport

How we know: HighCape Capital's portfolio page · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17M disclosed across 2 rounds · 2021–2026

▶$153.7KraisedMar 2026 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara FoxExecutive Officer, Director
  • Colleen CuffaroDirector
  • Nicholas J GalliExecutive Officer, Director
  • Kevin RakinDirector
  • Matthew CohenDirector
  • Ranjit BindraDirector
Offering amount
$10M
Amount sold
$153.7K
First sale
Feb 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.9MraisedSep 2021 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Colleen CuffaroExecutive Officer, Director
  • Anurag AgarwalDirector
  • Ranjit BindraExecutive Officer, Director
  • Kevin L. RakinExecutive Officer, Director
  • Stanley ChoyExecutive Officer
Offering amount
$40M
Amount sold
$16.9M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Alphina Therapeutics went on to found or lead other companies.

Ranjit BindraDirectorFounded Modifi Biosciences +1Kevin RakinDirectorFounded HighCape Capital

Competitors · 3

by search overlap
Eli Lilly12 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Intellia Therapeutics10 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Alphina Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Alphina Therapeutics nabs crack leaders hip team amid $45MM Series A financing - Alphina Therapeuticsalphinatx.com · Jun 2021Alphina Therapeutics - Teamalphinatx.com · Jun 2021

Frequently asked questions

What does Alphina Therapeutics do?
Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.
Who are Alphina Therapeutics's investors?
Alphina Therapeutics's investors include Canaan Partners, Connecticut Innovations, HighCape Capital, OUP (Osage University Partners).
How much funding has Alphina Therapeutics raised?
Alphina Therapeutics has disclosed $17M raised across 2 rounds.
Where is Alphina Therapeutics headquartered?
Alphina Therapeutics is headquartered in New Haven, US.